AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain
Open accessPublished version of a preprint
The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index; 10 of the 45 sources its claims cite were checked for support.
Abstract
Adeno-associated viral (AAV) vector-based gene therapy is gaining foothold as treatment for genetic neurological diseases with encouraging clinical results. Nonetheless, dose-dependent adverse events have emerged in recent clinical trials through mechanisms that remain unclear. We have modelled here the impact of AAV transduction in cell models of the human central nervous system (CNS), taking advantage of induced pluripotent stem cells. Our work uncovers vector-induced innate immune mechanisms that contribute to cell death. While empty AAV capsids were well tolerated, the AAV genome triggered p53-dependent DNA damage responses across CNS cell types followed by the induction of inflammatory responses. In addition, transgene expression led to MAVS-dependent activation of type I interferon responses. Formation of DNA damage foci in neurons and gliosis were confirmed in murine striatum upon intraparenchymal AAV injection. Transduction-induced cell death and gliosis could be prevented by inhibiting p53 or by acting downstream on STING- or IL-1R-mediated responses. Together, our work identifies innate immune mechanisms of vector sensing in the CNS that can potentially contribute to AAV-associated neurotoxicity. Costa-Verdera et. al describe a mechanism by which AAV vector genomes activate P53-mediated signalling in CNS cells involving downstream STING activation and pro-inflammatory responses. Inhibition of either P53 or STING prevented target-cell apoptosis and inflammatory signalling.
Overview
CoChat Summary
TL;DR
In hiPSC-derived CNS models and mouse striatum, genome-containing AAV vectors—not empty capsids—trigger p53-dependent DNA damage responses followed by inflammatory and type I IFN signalling, with transgene expression enhancing inflammation. p53, STING, or IL-1R inhibition reduces pro-inflammatory signalling and/or cell death, while MAVS mediates type I IFN.
Key findings
- Full AAV9, but not empty AAV9, induced DNA damage and death markers in hiPSC-derived neurons: increased p-γH2AX and cleaved caspase 3 (cC3) after 48 h; quantification used n = 9 coverslips untransduced, n = 5 empty, n = 11 full across 4 independent experiments. Empty AAV9 capsid caused no significant transcriptional changes versus untransduced controls, whereas full AAV9 did.
- In mixed 2D cultures and 150-day 3D brain spheroids, scRNAseq showed early p53 activation followed by inflammatory and type I IFN signatures; GFP expression was higher in astrocytes and oligodendrocytes than neurons. A non-expressing hAAT-GFP vector triggered milder signalling limited mainly to oxidative phosphorylation, p53, and DNA repair, while CAG-driven transgene expression enhanced pro-inflammatory pathways.
- In mice, bilateral intrastriatal AAV9-CAG-GFP (1 × 10^10 vg in 3 µl/hemisphere; 2 × 10^10 vg total) at 28 days induced p-γH2AX foci mainly in NeuN+ neurons, increased GFAP+Sox9+ astrocytes and Iba1+ microglia, and recruited CD45+ and CD3+ cells; snRNAseq used n = 2 mice/group, and IF used n = 3 AAV9 versus n = 2 vehicle.
- Mechanistically, p53 inhibition with GSE56 completely abrogated CXCL8 and IL-1β induction, partially prevented ISGs, and rescued cC3 and LDH release; H151 (STING) or Anakinra (IL-1R) prevented pro-inflammatory responses without affecting p21/GDF15, and H151 rescued cell death in 2D neurons and mixed cultures. MAVS knockout diminished ISGs but not p21 or IL-1β. In vivo, p53, cGAS, or STING inhibition decreased GFAP+ cells but had no effect on Iba1+ cells and showed no NeuN+ neurotoxicity in that experiment.
Methods
- Human iPSC-derived 2D neurons, astrocytes, mixed neuronal/glial cultures, and 3D brain spheroids (150 days) were transduced with AAV serotypes including AAV1, 2, 5, 6, 9, and Spk100, using full or empty capsids and CAG- or hAAT-driven transgenes; readouts included bulk RNAseq, scRNAseq, qPCR, flow cytometry, immunofluorescence, and CXCL8 ELISA.
- Adult male C57BL/6J mice received bilateral intrastriatal AAV9-CAG-GFP or vehicle and were sacrificed 28 days post-injection for snRNAseq and immunofluorescence; a separate inhibitor study used pifithrin-α, RU.521, or H151 with striatal sections assessed 8 weeks post-injection.
- Analyses included DESeq2, Hallmark GSEA, Seurat/Harmony or sctransform clustering, Cell Ranger, GSVA, and one-way ANOVA with Tukey or Bonferroni post-hoc tests.
Limitations
- Stated: vector signalling was overall lower in mice than in vitro, possibly due to lower transduction or species-specific responses; animal models are less predictive of clinical outcomes; cGAS/STING and MAVS contributions need confirmation in genetic mouse models; clinical impact remains to be elucidated; microglia contribution warrants further study; duration of the insult is hard to predict in vitro.
- Evident: the in vivo snRNAseq experiment used only n = 2 mice per group, and the IF comparison used n = 3 AAV9 versus n = 2 vehicle, limiting statistical power; the in vivo inhibitor experiment modulated GFAP+ cells but not Iba1+ cells, so gliosis effects were partial and cell-type restricted.
- Evident: 2D versus 3D differences may be confounded by longer transduction time, longer differentiation/maturation, or MOI effects; transgene-negative populations may still contain undetected vector genomes or receive paracrine signals, complicating attribution of effects to transgene expression alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
7 Valid · 0 Not valid · 23 Not checked · 99 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, targeting the CNS through systemic administration remains challenging and requires vector doses 10-to 100-times higher than those used to target the liver 2,3 .”
§ AAV vectors trigger DNA damage responsedependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain > Discussion
What the sources say
- Partly supportedcites [2] Costa Verdera, H., Kuranda, K. & Mingozzi, F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol. Ther. 28, 723–746 (2020). sourceExperimental — accuracy not yet measured
Our copy supports the directional part of the claim: the 'Gene Transfer to Motor Neurons and the Central Nervous System' section notes the physical separation of the CNS from the systemic circulation by the blood-brain barrier, and states that CSF administration 'requires higher vector doses' (though there the comparison is with direct intraparenchymal injection, not with liver targeting). It also reports the relevant doses separately — systemic AAV9-SMN for motor-neuron/CNS targeting at 6.7 x 10^13 and 2.0 x 10^14 vg/kg, with 'most of the vector delivered systemically ends up in the liver', versus liver-directed trials in the 'Liver Gene Transfer' section at ~5 x 10^11 to 2 x 10^13 vg/kg — but nowhere does the paper state or compute the specific '10- to 100-fold higher than for liver' magnitude attributed to it. That quantitative comparison is the citing authors' own derivation, not a statement of this source. (LLM, conf=0.65)
- Partly supportedcites [3] Perez, B. A., Shutterly, A., Chan, Y. K., Byrne, B. J. & Corti, M. Management of neuroinflammatory responses to AAV-mediated gene therapies for neurodegenerative diseases. Brain Sci. 10, 119 (2020). sourceExperimental — accuracy not yet measured
Our copy supports the qualitative core: Section 2.1 (Systemic Delivery) states that to achieve clinically relevant transgene expression, 'especially within the CNS, this route of administration requires high vector doses', and Section 2.2 notes CNS-directed delivery 'require[s] lower doses of vector'. However, no passage in our copy references the liver as the comparator, and no 10- to 100-fold figure versus liver dosing appears; the only quantitative magnitude given (Section 3.2, Route of Administration, ref [58]) is a 50-fold lower dose when AAV9 is delivered into CSF rather than systemically — a different comparator (CNS-directed vs systemic), not liver vs CNS. So the magnitude-and-liver part of the claim is not attributable to this source. (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Iba1 + cells expressed microglia activation markers such as Galectin-3 40 (Fig. S14D, F) and Gasdermin D (GSDMD) 41 (Fig. S14G, H).”
§ AAV vectors trigger DNA damage responsedependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain > AAV9-mediated CNS transduction induces pro-inflammatory and cell stress signalling in vivo
What the sources say
- Supportedcites [40] Ge, M. M. et al. Galectin-3 in microglia-mediated neuroinflammation: implications for central nervous system diseases. Curr. Neuropharmacol. 20, 2066–2080 (2022). source
The cited part of the sentence (ref 40) attributes to Tian et al. only that Galectin-3 is a microglial activation marker expressed in Iba1+ microglia; the Gasdermin D clause carries a separate citation (41) and is not judged here. Our copy states in the Abstract that Gal-3 'has been cumulatively revealed to be a crucial biomarker for microglial activation after injuries or diseases,' and throughout the review it describes activated microglia as Gal-3-positive (Galectin-3-IGF-R1 Signaling Pathway: Gal-3 up-regulated in proliferating microglia after MCAO; Galectin-3-TLRs: 'Gal-3, as an important molecule released by activated microglia'). The Ischemic/Stroke section explicitly couples the two markers, noting Hara et al. detected 'a transient upregulation of Gal-3 positive microglia in the hippocampal CA1' with 'Gal-3 and Iba-1 levels significantly suppressed after hypothermia treatment.' As a review it reports these findings from primary studies, which the rubric accepts as support. (LLM, conf=0.82)
- Not checked yetcites [41] Pollock, N. M. et al. Gasdermin D activation in oligodendrocytes and microglia drives inflammatory demyelination in progressive multiple sclerosis. Brain Behav. Immun. 115, 374–393 (2024). source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, studies in nonhuman primates (NHPs) and clinical trials have revealed that both local and systemic treatment with AAV vectors can induce dose-dependent toxicities in the central [7][8][9][10][11][12][13] and peripheral 14,15 nervous systems, characterized by neuronal loss in the brain parenchyma or in the dorsal root ganglia (DRG), respectively.”
§ AAV vectors trigger DNA damage responsedependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain > Abstract
What the sources say
- Not checked yetcites [7] Keiser, M. S. et al. Toxicity after AAV delivery of RNAi expression constructs into nonhuman primate brain. Nat. Med. 27, 1982–1989 (2021). source
- Not checked yetcites [8] Golebiowski, D. et al. Direct intracranial injection of AAVrh8 encoding monkey β-N-Acetylhexosaminidase causes neurotoxicity in the primate brain. Hum. Gene Ther. 28, 510–522 (2017). source
- Partly supportedcites [9] Rosenberg, J. B. et al. Safety of direct Intraparenchymal AAVrh.10-mediated central nervous system gene therapy for metachromatic leukodystrophy. Hum. Gene Ther. 32, 563–580 (2021). sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“While empty AAV capsids were well tolerated, the AAV genome triggered p53-dependent DNA damage responses across CNS cell types followed by the induction of inflammatory responses.”
§ AAV vectors trigger DNA damage responsedependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, transgene expression led to MAVS-dependent activation of type I interferon responses.”
§ AAV vectors trigger DNA damage responsedependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
62 more claims
Create a free account to see all 129 claims and to verify the 35 references still open.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 44
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Our previous work in mice and human iPSC-derived neural cells revealed that AAV vectors triggered neuroinflammation dependent on activation of DDR (40).”
From Intravitreal AAV vector delivery induces integrin-dependent ocular inflammation, complement activation, and antiviral and DNA damage responses (2026) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ AAV vectors trigger DNA damage responsedependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain > Data processing and graph-based clustering
“*, adjusted P < 0.05; **, adjusted P < 0.01; ***, adjusted P < 0.01”
§ AAV vectors trigger DNA damage responsedependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain > Additional information
“For all figures, *P < 0.05, **P < 0.01, ***P < 0.001.”
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Yu, G., Wang, L.-G., Han, Y., & He, Q.-Y. (2012) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2011.0118 · Cited by 36,259
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Fast, sensitive and accurate integration of single-cell data with Harmony
Korsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y., Brenner, M., Loh, P.-R., & Raychaudhuri, S. (2019) · Nature Methods · doi:10.1038/s41592-019-0619-0 · Cited by 10,488
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034
Dimensionality reduction for visualizing single-cell data using UMAP
Becht, E., McInnes, L., Healy, J., Dutertre, C.-A., Kwok, I. W. H., Ng, L. G., Ginhoux, F., & Newell, E. W. (2019) · Nature Biotechnology · doi:10.1038/nbt.4314 · Cited by 5,358
Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009) · Nature Biotechnology · doi:10.1038/nbt.1529 · Cited by 3,620
Research works printed but not linked: 1
- Golebiowski, D. et al. Direct intracranial injection of AAVrh8 encoding monkey beta-N-Acetylhexosaminidase causes neurotoxicity in the primate brain. Hum. Gene Ther. 28, 510–522 (2017). · DOI · Paper page
Cited by
Innate immune sensing of adeno-associated virus vectors
Cao, D., Byrne, B. J., de Jong, Y. P., Terhorst, C., Duan, D., Herzog, R. W., & Kumar, S. R. P. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.040 · Cited by 50
Treating Hearing Loss: From Cochlear Implantation to Gene Therapy
Zeng, F., Qi, J., Wu, C., Shu, Y., & Chai, R. (2025) · Advanced Science · doi:10.1002/advs.202509960 · Cited by 23
AAV NRF2 gene therapy preserves retinal structure and function in rodent models of oxidative damage
Gardner, A., Wang, S., Daniels, A., Li, D. D., Wu, C. C., Lin, L., Hong, C. M., Zhao, S. R., Born, R. T., Kruczek, K., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.005 · Cited by 12
Advancing Alzheimer’s research by improving disease modeling of secondary tauopathy
Roy, E. R., & Cao, W. (2025) · npj Dementia · doi:10.1038/s44400-025-00044-w · Cited by 5
“Inaddition,AAVvectorsmaybedeliveredtoadultmiceat distalsiteswithintheCNS,suchasintracerebroventricular 52 or intrathecal spaces 53 , avoiding mechanical injury to parenchymal sites of interest.”
InfluentialSafety of in vivo gene therapy in children: mechanisms and management of liver injury
Jeyaraj, R., Brown, L. K., Jagadisan, B., Muntoni, F., Baruteau, J., Gupte, G. L., Breuer, J., Gissen, P., Oo, Y. H., & Dhawan, A. (2026) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(25)00380-3 · Cited by 5
Metadata
- Authors
- Costa-Verdera, H., Meneghini, V., Fitzpatrick, Z., Abou Alezz, M., Fabyanic, E., Huang, X., Dzhashiashvili, Y., Ahiya, A., Mangiameli, E., Valeri, E., Crivicich, G., Piccolo, S., Cuccovillo, I., Caccia, R., Chan, Y. K., Bertin, B., Ronzitti, G., Engel, E. A., Merelli, I., Mingozzi, F., Gritti, A., Kuranda, K., & Kajaste-Rudnitski, A.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- Spark Therapeutics (United States) (US)
- The San Raffaele Telethon Institute for Gene Therapy (IT)
- Harvard University (US)
- Inserm (FR)
- ORCID
- Costa-Verdera, Helena
- Meneghini, Vasco
- Abou Alezz, Monah
- Fabyanic, Emily
- Huang, Xin
- Mangiameli, Elisabeth
- Valeri, Erika
- Crivicich, Giovanni
- Piccolo, Silvia
- Cuccovillo, Ivan
- Caccia, Roberta
- Chan, Ying Kai
- Bertin, Bérangère
- Ronzitti, Giuseppe
- Engel, Esteban A.
- Mingozzi, Federico
- Gritti, Angela
- Kuranda, Klaudia
- Kajaste-Rudnitski, Anna
- Venue
- Nature Communications
- Published
- 2025-04-18
- Volume
- 16
- Issue
- 1
- Pages
- 3694-3694
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC12008376
- OpenAlex
- W4409566313
- Semantic Scholar
- db0df95757227d3fc3fa03cfbb9bc728d2ed838c
- Cited by
- 32
- References
- 103
- Citations by year
- 2026: 20 · 2025: 11
- FWCI
- 18.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by-nc-nd)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion, cc-by-nc-nd)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Foundation for the National Institutes of Health (2022-BGTC003)
- European Federation of Pharmaceutical Industries and Associations (945473)
- European Commission (945473, HORIZON2020)
- Fondazione Telethon
- Spark Therapeutics
- H2020 European Research Council (819815)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- adeno-associated virus vectors, AAV gene therapy, neurotoxicity, DNA damage response, p53, STING, innate immunity, type I interferon, MAVS, gliosis, iPSC-derived neurons, pro-inflammatory signaling, AAV capsid
- MeSH terms
- Dependovirus, Animals, Brain, Central Nervous System, DNA Damage, Genetic Vectors, Gliosis, Humans, Immunity, Innate, Inflammation, Mice, Inbred C57BL, Neurons, Transduction, Genetic, Genetic Therapy, Signal Transduction, Tumor Suppressor Protein p53, Mice, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain. https://app.cochat.ai/papers/10.1038/s41467-025-58778-3
- The paper
- Costa-Verdera, H., Meneghini, V., Fitzpatrick, Z., Abou Alezz, M., Fabyanic, E., Huang, X., Dzhashiashvili, Y., Ahiya, A., Mangiameli, E., Valeri, E., Crivicich, G., Piccolo, S., Cuccovillo, I., Caccia, R., Chan, Y. K., Bertin, B., Ronzitti, G., Engel, E. A., Merelli, I., . . . Kajaste-Rudnitski, A. (2025). AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain. Nature Communications. https://doi.org/10.1038/s41467-025-58778-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.